At a glance
ClinicalIndex Comparison RecordN/ACompleted· 150 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Characteristics and Treatment Outcomes of Patients With Autoimmune Hemolytic Anemia in Assiut University Hospital
In Brief
An observational study for Autoimmune Hemolytic Anemia. Completed, enrolled 150 participants across 1 site.
Detailed Summary
Autoimmune hemolytic anemia is characterized by shortened red blood cell survival and a positive Coombs test. The responsible autoantibodies may be either warm reactive or cold reactive. The rate of hemolysis and the severity of the anemia may vary from mild to severe and life-threatening. Diagnosis is made in the laboratory by the findings of anemia, reticulocytosis, a positive Coombs test, and specific serologic tests. The prognosis is generally good but renal failure and death sometimes occur, especially in cases mediated by drugs.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAutoimmune Hemolytic Anemia
CountriesEgypt
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
First PostedAug 2017
Enrollment StartOct 2017
Primary CompletionJan 2021
TodayJul 2026
First PostedAug 31, 2017
Enrollment StartOct 1, 2017
Primary CompletionJan 24, 2021
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 8.8 years ago